Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings: 2014-2025

Historic Retained Earnings for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to -$1.2 billion.

  • Viridian Therapeutics, Inc.\DE's Retained Earnings fell 32.96% to -$1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.2 billion, marking a year-over-year decrease of 32.96%. This contributed to the annual value of -$995.9 million for FY2024, which is 37.19% down from last year.
  • Viridian Therapeutics, Inc.\DE's Retained Earnings amounted to -$1.2 billion in Q3 2025, which was down 2.92% from -$1.2 billion recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Retained Earnings registered a high of -$297.3 million during Q1 2021, and its lowest value of -$1.2 billion during Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$839.4 million (2024), whereas its average is -$869.4 million.
  • Data for Viridian Therapeutics, Inc.\DE's Retained Earnings shows a maximum YoY plummeted of 75.08% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$358.3 million in 2021, then plummeted by 36.25% to -$488.2 million in 2022, then tumbled by 48.70% to -$725.9 million in 2023, then slumped by 37.19% to -$995.9 million in 2024, then slumped by 32.96% to -$1.2 billion in 2025.
  • Its last three reported values are -$1.2 billion in Q3 2025, -$1.2 billion for Q2 2025, and -$1.1 billion during Q1 2025.